GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (XTER:DMP) » Definitions » 3-Year FCF Growth Rate

Dermapharm Holding SE (XTER:DMP) 3-Year FCF Growth Rate : -4.80% (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE 3-Year FCF Growth Rate?

Dermapharm Holding SE's Free Cash Flow per Share for the three months ended in Dec. 2024 was €1.12.

During the past 12 months, Dermapharm Holding SE's average Free Cash Flow per Share Growth Rate was -8.30% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -4.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 25.10% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 27.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Dermapharm Holding SE was 95.90% per year. The lowest was -22.60% per year. And the median was 18.75% per year.


Competitive Comparison of Dermapharm Holding SE's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's 3-Year FCF Growth Rate falls into.


;
;

Dermapharm Holding SE 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Dermapharm Holding SE  (XTER:DMP) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Dermapharm Holding SE 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
Executives
Wilhelm Beier Supervisory Board
Dr. Hans-georg Feldmeier Board of Directors
Christof Dreibholz Board of Directors
Lothar Lanz Supervisory Board
Anja Schorn Board Member Themis Beteiligungs-AG
Hilde Neumeyer Board of Directors

Dermapharm Holding SE Headlines

No Headlines